Pharmacoeconomic evaluation and resource implications of Zytiga ® (abiraterone acetate) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel-based chemotherapy.
Rapid Review
| Commenced | Completed | Outcome |
| 21/10/2011 | 02/11/2011 | Full Pharmacoeconomic Evaluation Recommended. |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 12/12/2011 | 22/05/12 | Reimbursement not recommended at the submitted price. |
The NCPE believe that, at the submitted price, Abiraterone Acetate (Zytiga®) is not cost-effective for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel-based chemotherapy.
May 2014
The HSE has approved reimbursement following confidential price negotiations.